SAN DIEGO, Dec. 15, 2014 (GLOBE NEWSWIRE) -- Biocept, Inc. (Nasdaq:BIOC), a molecular oncology diagnostics company specializing in circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) biomarker analysis, today announced that it has been granted a patent in South Korea for its fluidic microfluidic channel. The patent, Detection or Isolation of Target Molecules Using a Microchannel Apparatus, is the subject of Korean Patent Application No. 10-2009-7003339.
The granted patent covers manufacture and use of Biocept's proprietary microfluidic channel to capture rare cells, including CTCs shed into the blood from solid tumors, and a wide array of other biologically significant molecules. Using a blood-based, liquid biopsy, Biocept uses a simple blood draw instead of painful and expensive solid tumor needle biopsies to test for biomarkers associated with cancer and to aid in treatment decisions. Biocept has previously announced patents awarded to the Company for its core microfluidic channel technology in the U.S., the EU and China.
Lyle Arnold, Ph.D., Biocept Chief Scientific Officer, said, "The granting of this patent expands Biocept's international reach in the protection of its microfluidic channel for capturing and gathering treatment information from CTCs. The patent potentially enables Biocept to bring the power of the liquid biopsy to a new international market, thereby enabling Korean physicians to obtain valuable biomarker information to help optimize treatment outcomes."
Michael Nall, President and Chief Executive Officer said, "We are pleased to see continued success in the issuance of patents both in the U.S. and globally. This latest patent in South Korea adds to our already robust intellectual property portfolio and positions us well for international expansion, through licensing and partnership opportunities, as we continue to demonstrate a strong IP position worldwide."
About Biocept, Inc.
Biocept, Inc., headquartered in San Diego, California, is a commercial stage oncology diagnostics company focused on providing information on patients' tumors to physicians using its proprietary technology platform to help improve individual patient treatment. Biocept has developed proprietary technology platforms for capture and analysis of circulating tumor cells and circulating tumor DNA utilizing a standard blood sample to provide physicians with important prognostic and predictive information to enhance individual treatment of their patients with cancer. Biocept currently offers its OncoCEE-BRTM test for breast cancer and OncoCEE-LUTM for lung cancer and plans to introduce additional biomarker tests for breast, lung, colorectal, prostate and other solid tumors based on its proprietary technology platforms.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including without limitation statements as to medical trends, expansion of offerings, including internationally, and anticipated product introductions, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our SEC filings, including without limitation our need to grow our business and our operations, our need for capital, and the effects of reimbursement limitations and other health care statutory and regulatory initiatives. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this release. Readers are advised to review our filings with the Securities and Exchange Commission, which can be accessed over the Internet at the SEC's website located at www.sec.gov.
CONTACT: Investor Contact: The Ruth Group David Burke/Lee Roth (646) 536-7009 / (646) 536-7012 firstname.lastname@example.orgemail@example.com Media Contact: The Ruth Group Melanie Sollid-Penton (646) 536-7023 firstname.lastname@example.org